<DOC>
	<DOCNO>NCT00533364</DOCNO>
	<brief_summary>This study set determine whether soluble beta-glucan ( SBG ) - unfavourable side effect - beneficial treatment effect give combination standard antibody chemotherapy patient breast cancer .</brief_summary>
	<brief_title>Effect SBG Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women histologically/cytologically confirm locally advance metastatic breast cancer 2 . Primary tumor metastasis HER2ICH3+ FISH+ 3 . Measurable nonmeasurable disease 4 . The patient must receive treatment combination trastuzumab vinorelbine previously 5 . Expected lifetime 12 week 6 . Age ≥ 18 year 7 . Performance status ≤ 2 accord World Health Organization ( WHO ) scale 8 . The patient must able comply protocol 9 . Verbal write informed consent 1 . Women pregnant breastfeeding . A negative pregnancy test must provide screening period fertile woman . Fertile woman must use effective contraceptive method 2 . Clinical symptom indicate central nervous system involvement 3 . Other current former malignant disease , exception adequately treat cured carcinoma situ cervicis uteri basocellular skin carcinoma 4 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % normal range 5 . Reduced bone marrow function define leukocyte count &lt; 3.0 x 109/l neutrophil count &lt; 1.5 x 109/l , thrombocyte count ≤ 100 x 109/l 6 . Reduced liver function define bilirubin &gt; 3 x upper normal limit and/or ASAT/ALAT &gt; 3 x upper normal limit and/or alkaline phosphatase &gt; 3 x upper normal limit . 7 . Reduced renal function define serum creatinine &gt; 2 x upper normal limit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>